IN ADULTS AND CHILDREN
Type 2 or 3 SMA (later-onset)
IN INFANTS
Type 1 SMA (infantile-onset)
The safety profile of Evrysdi in infants treated before symptoms of SMA appear (presymptomatic) was consistent with the safety profile of Evrysdi in infants with Type 1 SMA and adults and children with Type 2 or 3 SMA.
These are not all of the possible side effects of Evrysdi. For more information on the possible risks and benefits of Evrysdi, speak to your healthcare provider.
No one in the clinical studies stopped taking Evrysdi because of side effects of treatment*
*As of March 2022.
Initial safety findings from people who previously took other approved or investigational SMA medications have been consistent with the safety findings from studies in adults, children, and infants who only took Evrysdi.
Información de prescripción de Evrysdi® (risdiplam). Genentech, Inc.
Información de prescripción de Evrysdi® (risdiplam). Genentech, Inc.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.